Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC23H25BrN6O3 |
InChIKeyZKGZTDISFHHJHP-DFXFOWLGSA-N |
CAS Registry3054228-46-2 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | China | 01 Mar 2024 |





